Incidence of diabetes mellitus‑related comorbidities among patients attending two major HIV clinics in Botswana: a 12‑year retrospective cohort study
View/ Open
Date
2018-02-01Author
Rankgoane‑Pono, Goabaone
Tshikuka, Jose Gaby
Magafu, Mgaywa Gilbert Mjungu Damas
Masupe, Tiny
Molefi, Mooketsi
Hamda, Shimeles Genna
Setlhare, Vincent
Tapera, Roy
Mbongwe, Bontle
Publisher
BioMed Central, www.biomedcentral.comType
Published ArticleMetadata
Show full item recordAbstract
Objectives: Exposure to combination antiretroviral therapy (cART) is associated with the development of diabetes
mellitus related comorbidities (DRCs). This study aims to: (i) estimate the incidence of DRCs among cART recipients, (ii) assess the time-to-event (development of DRC) and, (iii) compare survival function between recipients on first-line regimen and those on second-, third-line cART regimen.
Results: The incidence of DRCs was 26.8/1000 person-years, with total time of exposure of 3316 person-years. The average time to event for all the three regimens was 11.72 ± 0.20 years. The first-line cART regimen had a shorter mean ± SE of 10.59 ± 0.26 years to the event compared to 12.69 ± 0.24 years for the second-, third-line cART regimen.
Recipients on the first-line had a shorter survival than recipients on second-, third-line cART (Log-rank X2
= 8.98, p < 0.003). Data from this study showed that the risk of developing DRCs per year of exposure was significantly greater for patients on first-line compared to those who were on second-, third-line regimen; which, suggests that monitoring of cART long-term side effects and regular reviewing of cART regimens is important. Meticulous selection of drug combinations is a key to improving recipients’ survival.